Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

The tolerability issue of generic imatinib in patients with chronic myeloid leukemia (Comment on Adi J. Klil-Drori et al., Haematologica 2019;104(7):e293).

Eskazan AE, Soysal T.

Haematologica. 2019 Jul;104(7):e330. doi: 10.3324/haematol.2019.222000. No abstract available.

2.

An alternative way - tyrosine kinase inhibitor (TKI) de-escalation - to discontinue TKIs in order to achieve treatment-free remission.

Kunbaz A, Eskazan AE.

Expert Rev Hematol. 2019 Jul;12(7):477-480. doi: 10.1080/17474086.2019.1623666. Epub 2019 Jun 5. No abstract available.

PMID:
31166812
3.

Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura.

Elverdi T, Eskazan AE.

Drug Des Devel Ther. 2019 Apr 17;13:1251-1258. doi: 10.2147/DDDT.S134470. eCollection 2019. Review.

4.

The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations.

Soysal T, Eskazan AE, Serin I, Sadri S, Keskin D, Ozgur Yurttas N, Berk S, Erdogan Ozunal I, Salihoglu A, Ar MC, Ongoren S, Baslar Z, Ozbek U, Aydin Y.

Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e377-e384. doi: 10.1016/j.clml.2019.03.028. Epub 2019 Apr 4.

PMID:
31088736
5.

Coexistence of Hermansky-Pudlak syndrome and JAK2V617F-positive essential thrombocythemia.

Eskazan T, Erturkuner SP, Isildar B, Eskazan AE, Ar MC, Atay K, Baslar Z, Tasyurekli M.

Ultrastruct Pathol. 2019;43(1):94-98. doi: 10.1080/01913123.2019.1593269. Epub 2019 Apr 1.

PMID:
30932722
6.

Is measuring plasma imatinib trough levels still an appropriate way for predicting responses in patients with chronic myeloid leukemia?

Eskazan AE.

Leuk Lymphoma. 2019 Aug;60(8):2094-2095. doi: 10.1080/10428194.2019.1571202. Epub 2019 Feb 4. No abstract available.

PMID:
30714448
7.
8.

Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?

Eskazan AE.

Cancer. 2018 Nov 1;124(21):4260-4261. doi: 10.1002/cncr.31682. Epub 2018 Oct 1. No abstract available.

PMID:
30276792
9.

Imatinib mesylate in the management of chemotherapy-induced pulmonary toxicity: a double-edged sword.

Eskazan AE.

Acta Oncol. 2019 Jan;58(1):123-124. doi: 10.1080/0284186X.2018.1502469. Epub 2018 Aug 14. No abstract available.

PMID:
30106325
10.

Vincristine as an Adjunct to Therapeutic Plasma Exchange for Thrombotic Thrombocytopenic Purpura: A Single-Institution Experience

Öngören S, Salihoğlu A, Apaydın T, Sadri S, Eşkazan AE, Ar MC, Elverdi T, Başlar Z, Aydın Y, Soysal T.

Balkan Med J. 2018 Nov 15;35(6):417-421. doi: 10.4274/balkanmedj.2017.1215. Epub 2018 Jul 3.

11.

Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors.

Erbilgin Y, Eskazan AE, Hatirnaz Ng O, Salihoglu A, Elverdi T, Firtina S, Tasar O, Mercan S, Sisko S, Khodzhaev K, Ongoren S, Ar MC, Baslar Z, Soysal T, Sayitoglu M, Ozbek U.

Leuk Lymphoma. 2019 Jan;60(1):200-207. doi: 10.1080/10428194.2018.1473573. Epub 2018 Jul 2.

PMID:
29965782
12.

Evolving treatment strategies in CML - moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes?

Eşkazan AE.

Br J Clin Pharmacol. 2018 Aug;84(8):1635-1638. doi: 10.1111/bcp.13637. Epub 2018 Jun 3. No abstract available.

PMID:
29862545
13.

Cytopenia in adult brucellosis patients.

Kaya S, Elaldi N, Deveci O, Eskazan AE, Bekcibasi M, Hosoglu S.

Indian J Med Res. 2018 Jan;147(1):73-80. doi: 10.4103/ijmr.IJMR_542_15.

14.

The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia.

Ercaliskan A, Eskazan AE.

Cancer. 2018 Oct 1;124(19):3806-3818. doi: 10.1002/cncr.31408. Epub 2018 Apr 25. Review.

PMID:
29694669
15.

The issue of financial toxicity in the management of chronic myeloid leukemia with blast crisis.

Eskazan AE.

J Med Econ. 2018 Jul;21(7):709-711. doi: 10.1080/13696998.2018.1467919. Epub 2018 May 8. No abstract available.

PMID:
29673265
16.

Dasatinib-induced pulmonary arterial hypertension.

Özgür Yurttaş N, Eşkazan AE.

Br J Clin Pharmacol. 2018 May;84(5):835-845. doi: 10.1111/bcp.13508. Epub 2018 Mar 6. Review.

17.

Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience.

Öngören Ş, Eşkazan AE, Berk S, Elverdi T, Salihoğlu A, Ar MC, Başlar Z, Aydın Y, Tüzüner N, Soysal T.

Turk J Haematol. 2017 Dec 1;34(4):291-299. doi: 10.4274/tjh.2016.0443.

18.

Further augmentation of molecular responses with dasatinib therapy in chronic myeloid leukemia patients who gained major molecular response under imatinib.

Eskazan AE.

Int J Clin Oncol. 2018 Apr;23(2):400-401. doi: 10.1007/s10147-017-1214-y. Epub 2017 Nov 13. No abstract available.

PMID:
29134363
19.

Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.

Eskazan AE.

N Engl J Med. 2017 Nov 9;377(19):1901. doi: 10.1056/NEJMc1711340. No abstract available.

PMID:
29120132
20.

Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update.

Eskazan AE, Keskin D.

Ther Adv Hematol. 2017 Sep;8(9):237-243. doi: 10.1177/2040620717719851. Epub 2017 Jul 25. Review.

21.

Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.

Ongoren S, Eskazan AE, Suzan V, Savci S, Erdogan Ozunal I, Berk S, Yalniz FF, Elverdi T, Salihoglu A, Erbilgin Y, Iseri SA, Ar MC, Baslar Z, Aydin Y, Tuzuner N, Ozbek U, Soysal T.

Hematology. 2018 May;23(4):212-220. doi: 10.1080/10245332.2017.1385193. Epub 2017 Oct 9. Review.

PMID:
28990873
22.

Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec.

Eskazan AE, Sadri S, Keskin D, Ayer M, Kantarcioglu B, Demirel N, Aydin D, Aydinli F, Yokus O, Ozunal IE, Berk S, Yalniz FF, Elverdi T, Salihoglu A, Ar MC, Ongoren S, Baslar Z, Aydin Y, Tuzuner N, Ozbek U, Soysal T.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):804-811. doi: 10.1016/j.clml.2017.07.255. Epub 2017 Aug 4.

PMID:
28847475
23.

Vascular Adverse Events During Long-term Nilotinib Therapy in Patients With Chronic Myeloid Leukemia.

Eskazan AE.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):e63-e64. doi: 10.1016/j.clml.2017.07.010. Epub 2017 Aug 1. No abstract available.

PMID:
28830672
24.

Comment and response to: the significance of early warning in chronic myeloid leukemia.

Eskazan AE, Ar MC, Soysal T.

Expert Rev Hematol. 2018 Apr;11(4):267-268. doi: 10.1080/17474086.2017.1340719. Epub 2017 Jun 15. No abstract available.

PMID:
28598700
25.

Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?

Eskazan AE, Ozmen D.

Expert Rev Hematol. 2017 Jul;10(7):583-586. doi: 10.1080/17474086.2017.1339599. Epub 2017 Jun 13. No abstract available.

PMID:
28586242
26.

Additional chromosomal abnormalities at diagnosis or during tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

Eskazan AE.

Leuk Lymphoma. 2017 Oct;58(10):2516-2517. doi: 10.1080/10428194.2017.1295145. Epub 2017 Feb 28. No abstract available.

PMID:
28278707
27.

Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors.

Yalnız FF, Akkoç N, Salihoğlu A, Ar MC, Öngören Ş, Eşkazan AE, Soysal T, Aydın Y.

Turk J Haematol. 2017 Aug 2;34(3):233-238. doi: 10.4274/tjh.2016.0397. Epub 2017 Mar 8.

28.

Do all patients with chronic myeloid leukemia need to receive interferon during pregnancy?

Eskazan AE.

Leuk Lymphoma. 2017 Aug;58(8):2019-2020. doi: 10.1080/10428194.2016.1272685. Epub 2017 Jan 16. No abstract available.

PMID:
28092993
29.

Upfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase.

Eskazan AE.

Expert Opin Pharmacother. 2017 Feb;18(3):325-326. doi: 10.1080/14656566.2017.1282697. Epub 2017 Jan 23. No abstract available.

PMID:
28085518
30.

Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations.

Keskin D, Sadri S, Eskazan AE.

Drug Des Devel Ther. 2016 Oct 13;10:3355-3361. eCollection 2016. Review.

31.

Critical appraisal of European LeukemiaNet (ELN) 2013 recommendations for the management of chronic myeloid leukemia: is it early for a warning?

Eskazan AE, Ar MC, Soysal T.

Expert Rev Hematol. 2016 Oct;9(10):919-21. doi: 10.1080/17474086.2016.1231572. Epub 2016 Sep 8. No abstract available.

PMID:
27606433
32.

Bortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpura.

Eskazan AE.

Ann Hematol. 2016 Oct;95(11):1751-6. doi: 10.1007/s00277-016-2804-x. Epub 2016 Sep 3. Review.

PMID:
27590601
33.

Co-administration of cyclosporine A and imatinib among patients with Philadelphia chromosome-positive leukemias in the post-transplant setting.

Eskazan AE.

Eur J Clin Pharmacol. 2016 Dec;72(12):1537-1538. Epub 2016 Aug 25. No abstract available.

PMID:
27558360
34.

Congenital Dyserythropoietic Anemia Type 1: Report of One Patient and Analysis of Previously Reported Patients Treated with Interferon Alpha.

Salihoglu A, Elverdi T, Eskazan AE, Eyice D, Bavunoglu I, Ar MC, Ongoren S, Guzel E, Baslar Z, Tunckale A, Tuzuner N, Soysal T.

Indian J Hematol Blood Transfus. 2016 Jun;32(Suppl 1):272-7. doi: 10.1007/s12288-015-0600-8. Epub 2015 Sep 21.

35.

Treatment of patients with immune thrombocytopenia admitted to the emergency room.

Bavunoğlu I, Eşkazan AE, Ar MC, Cengiz M, Yavuzer S, Salihoğlu A, Öngören Ş, Tunçkale A, Soysal T.

Int J Hematol. 2016 Aug;104(2):216-22. doi: 10.1007/s12185-016-2003-5. Epub 2016 Apr 29.

PMID:
27129318
36.

Second primary malignancies in chronic myeloid leukemia patients.

Caliskan T, Eskazan AE.

J Cancer Res Ther. 2015 Oct-Dec;11(4):1042. doi: 10.4103/0973-1482.154928. No abstract available.

37.

Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia.

Tanrikulu Simsek E, Eskazan AE, Cengiz M, Ar MC, Ekizoglu S, Salihoglu A, Gulturk E, Elverdi T, Ongoren Aydin S, Senem Demiroz A, Buyru AN, Baslar Z, Ozbek U, Ferhanoglu B, Aydin Y, Tuzuner N, Soysal T.

J Clin Pathol. 2016 Sep;69(9):810-6. doi: 10.1136/jclinpath-2015-203320. Epub 2016 Jan 25.

PMID:
26811428
38.

Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in a Developing Country.

Eskazan AE.

Clin Ther. 2016 Mar;38(3):680-1. doi: 10.1016/j.clinthera.2016.01.003. Epub 2016 Jan 22. No abstract available.

PMID:
26811186
39.

Pleural tuberculosis in a patient with untreated type 1 Gaucher disease.

Dulgar O, Eskazan AE, Ersen E, Demiroz AS, Turna A, Oz B, Tuzuner N.

J Infect Chemother. 2016 Jan;22(1):53-7. doi: 10.1016/j.jiac.2015.08.009. Epub 2015 Oct 12.

PMID:
26459658
40.

Comparison of International Prognostic Index and NCCN-IPI in 324 patients with de novo diffuse large B-cell lymphoma: a multi-center retrospective analysis.

Öztürk E, Özbalak M, Berk S, Erdoğan I, Avşar E, Dolgun A, Çetiner M, Mandel NM, Yalnız FF, Elverdi T, Salihoğlu A, Eşkazan AE, Ar MC, Öngören Ş, Başlar Z, Aydın Y, Soysal T, Ferhanoğlu B.

Leuk Lymphoma. 2016 May;57(5):1211-4. doi: 10.3109/10428194.2015.1079319. Epub 2015 Oct 12. No abstract available.

PMID:
26294270
41.

Treatment and Outcome of Primary and Secondary Thrombotic Microangiopathies.

Eskazan AE, Salihoglu A.

Am J Nephrol. 2015;41(6):427-8. doi: 10.1159/000437002. Epub 2015 Jul 14. No abstract available.

42.

Can Positron Emission Tomography and Computed Tomography Be a Substitute for Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Patients with Hodgkin's or Non-Hodgkin's Lymphoma?

Çetin G, Çıkrıkçıoğlu MA, Özkan T, Karatoprak C, Ar MC, Eşkazan AE, Ayer M, Cerit A, Gözübenli K, Uysal BB, Erdem S, Ergül N, Tatar G, Çermik TF.

Turk J Haematol. 2015 Sep;32(3):213-9. doi: 10.4274/tjh.2013.0336.

43.

The Changing Epidemiology of Bloodstream Infections and Resistance in Hematopoietic Stem Cell Transplantation Recipients.

Yemişen M, Balkan İİ, Salihoğlu A, Eşkazan AE, Mete B, Ar MC, Öngören Ş, Başlar Z, Özaras R, Saltoğlu N, Mert A, Ferhanoğlu B, Öztürk R, Tabak F, Soysal T.

Turk J Haematol. 2016 Sep 5;33(3):216-22. doi: 10.4274/tjh.2014.0378. Epub 2015 May 4.

44.

Acute colitis presenting with hematochezia in a patient with chronic myeloid leukemia during dasatinib therapy.

Eskazan AE, Hatemi İ, Öngören Aydın S, Ar MC, Soysal T.

Turk J Gastroenterol. 2014 Dec;25 Suppl 1:233. doi: 10.5152/tjg.2014.5281. No abstract available.

45.

Relapse after allogeneic hematopoietic stem cell transplant in patients with chronic myeloid leukemia: tyrosine kinase inhibitors, donor lymphocyte infusions or both?

Eskazan AE, Erdogan I, Berk S, Yalniz FF, Elverdi T, Salihoglu A, Soysal T.

Leuk Lymphoma. 2015;56(10):2995-6. doi: 10.3109/10428194.2015.1026819. Epub 2015 Mar 28. No abstract available.

PMID:
25747967
46.

Generic imatinib in the treatment of chronic myeloid leukemia: Cerrahpaşa experience.

Eskazan AE, Soysal T.

J Oncol Pharm Pract. 2016 Apr;22(2):382-4. doi: 10.1177/1078155215570766. Epub 2015 Feb 2.

PMID:
25644376
47.

Radotinib in the treatment of chronic phase chronic myeloid leukemia patients.

Eskazan AE, Soysal T.

Haematologica. 2015 Jan;100(1):e39. doi: 10.3324/haematol.2014.117846. No abstract available.

48.

Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options.

Çetin G, Eşkazan AE, Ar MC, Aydın ŞÖ, Ferhanoğlu B, Soysal T, Başlar Z, Aydın Y.

Turk J Haematol. 2014 Dec 5;31(4):374-80. doi: 10.4274/tjh.2013.0004.

49.

The current situation and future aspects of cost-effectiveness in chronic myeloid leukemia treatment.

Eskazan AE, Soysal T.

Leuk Lymphoma. 2015 May;56(5):1554-5. doi: 10.3109/10428194.2014.975701. Epub 2014 Nov 19. No abstract available.

PMID:
25330444
50.

Spondylodiscitis: evaluation of patients in a tertiary hospital.

Kaya S, Ercan S, Kaya S, Aktas U, Kamasak K, Ozalp H, Cinar K, Duymus R, Boyaci MG, Akkoyun N, Eskazan AE, Temiz H.

J Infect Dev Ctries. 2014 Oct 15;8(10):1272-6. doi: 10.3855/jidc.4522.

Supplemental Content

Loading ...
Support Center